HRP20220044T1 - Rnk replikon za univerzalnu i efikasnu ekspresiju gena - Google Patents
Rnk replikon za univerzalnu i efikasnu ekspresiju gena Download PDFInfo
- Publication number
- HRP20220044T1 HRP20220044T1 HRP20220044TT HRP20220044T HRP20220044T1 HR P20220044 T1 HRP20220044 T1 HR P20220044T1 HR P20220044T T HRP20220044T T HR P20220044TT HR P20220044 T HRP20220044 T HR P20220044T HR P20220044 T1 HRP20220044 T1 HR P20220044T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- composition according
- protein
- rna
- replicon
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 241000710929 Alphavirus Species 0.000 claims 10
- 108700026244 Open Reading Frames Proteins 0.000 claims 7
- 230000010076 replication Effects 0.000 claims 7
- 150000002632 lipids Chemical class 0.000 claims 6
- 239000002245 particle Substances 0.000 claims 6
- 108091027544 Subgenomic mRNA Proteins 0.000 claims 5
- -1 cationic lipid Chemical class 0.000 claims 3
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims 2
- 108020005350 Initiator Codon Proteins 0.000 claims 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 2
- 101710172711 Structural protein Proteins 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 claims 2
- 239000002479 lipoplex Substances 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims 1
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 claims 1
- 241000710961 Semliki Forest virus Species 0.000 claims 1
- PFNFFQXMRSDOHW-UHFFFAOYSA-N Spermine Natural products NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims 1
- 108091081024 Start codon Proteins 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 108091036078 conserved sequence Proteins 0.000 claims 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
- 229940063675 spermine Drugs 0.000 claims 1
- 150000003512 tertiary amines Chemical group 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (15)
1. Farmaceutska kompozicija koja sadrži RNK replikon i izborno farmaceutski prihvatljiv razrjeđivač, i/ili farmaceutski prihvatljiv ekscipijens i/ili farmaceutski prihvatljiv nosač i/ili farmaceutski prihvatljiv vehikul, gdje navedeni replikon sadrži modificiranu 5’ sekvencu prepoznavanja replikacije alfavirusa, pri čemu je modificirana 5’ sekvenca prepoznavanja replikacije naznačena time, što su svi inicijacijski kodoni uklonjeni iz konzerviranog elementa sekvence 2 (CSE 2) nativne 5’ sekvence prepoznavanja replikacije alfavirusa i gdje modificirana 5’ sekvenca prepoznavanja replikacije sadrži jednu ili više dodatnih nukleotidnih izmjena koje kompenziraju poremećaje uparivanja nukleotida unutar jedne ili više struktura drška-petlja (SL) koji su uvedeni uklanjanjem inicijacijskih kodona,
pri čemu se navedeni CSE 2 proteže od SL2 do SL4 i sadrži nativni inicijacijski kodon koji kodira prve aminokiselinske ostatke alfavirusnog nestrukturnog proteina nsP1, i
gdje se modificirana 5’ sekvenca prepoznavanja replikacije karakterizira predviđenom sekundarnom strukturom koja je ekvivalentna predviđenoj sekundarnoj strukturi 5’ sekvence prepoznavanja replikacije alfavirusne genomske RNK.
2. Farmaceutska kompozicija prema patentnom zahtjevu 1, gdje RNK replikon sadrži 3’ sekvencu prepoznavanja replikacije.
3. Farmaceutska kompozicija prema patentnom zahtjevu 1 ili 2, gdje RNK replikon sadrži prvi otvoreni okvir čitanja koji kodira protein od interesa, pri čemu poželjno protein od interesa može bit eksprimiran sa RNK replikona kao matrice.
4. Farmaceutska kompozicija prema patentnom zahtjevu 3, gdje RNK replikon sadrži subgenomski promotor koji kontrolira proizvodnju subgenomske RNK koja sadrži prvi otvoreni okvir čitanja koji kodira protein od interesa, pri čemu poželjno protein od interesa kodiran prvim otvorenim okvirom čitanja može biti eksprimiran sa RNK replikona i subgenomske RNK.
5. Farmaceutska kompozicija prema patentnom zahtjevu 3, gdje RNK replikon sadrži subgenomski promotor koji kontrolira proizvodnju subgenomske RNK koja sadrži drugi otvoreni okvir čitanja koji kodira protein od interesa, koji su poželjno smješteni nizvodno od prvog otvorenog okvira čitanja koji kodira protein od interesa.
6. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 3 do 5, gdje je protein od interesa kodiran prvim i/ili drugim otvorenim okvirom čitanja funkcionalni alfavirusni nestrukturni protein.
7. Farmaceutska kompozicija prema patentnom zahtjevu 6, gdje replikon može biti repliciran pomoću funkcionalnog alfavirusnog nestrukturnog proteina.
8. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1 do 5, gdje replikon ne sadrži otvoreni okvir čitanja koji kodira funkcionalni alfavirusni nestrukturni protein.
9. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1 do 5 i 8, koja dodatno sadrži RNK konstrukt za ekspresiju funkcionalnog alfavirusnog nestrukturnog proteina,
gdje RNK replikon može biti repliciran pomoću funkcionalnog alfavirusnog nestrukturnog proteina in trans.
10. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1 do 9, gdje je alfavirus virus Semliki šume.
11. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1 do 10, koja sadrži formulaciju u vidu čestica RNK replikona, pri čemu je čestica ili proteinska čestica ili čestica koja sadrži lipide.
12. Farmaceutska kompozicija prema patentnom zahtjevu 11, gdje čestica koja sadrži lipide sadrži najmanje jedan kationski lipid i gdje je navedeni kationski lipid poželjno 1,2-di-O-oktadecenil-3-trimetilamonij propan (DOTMA); dimetildioktadecilamonij (DDAB); 1,2-dioleoil-3-trimetilamonij-propan (DOTAP); 1,2-dioleoil-3-dimetilamonij-propan (DODAP); 1,2-diaciloksi-3-dimetilamonij propani; 1,2-dialkiloksi-3-dimetilamonij propani; dioktadecildimetil amonij klorid (DODAC), 1,2-dimiristoiloksipropil-1,3-dimetilhidroksietil amonij (DMRIE) i 2,3-dioleoiloksi-N-[2(spermin karboksamid)etil]-N,N-dimetil-1-propanamij trifluoroacetat (DOSPA), gdje kationski lipidi poželjno također uključuju lipide sa tercijarnom aminskom grupom, uključujući 1,2-dilinoleiloksi-N,N-dimetil-3-aminopropan (DLinDMA).
13. Farmaceutska kompozicija prema patentnom zahtjevu 11, gdje je čestica koja sadrži lipide kompleks lipid/RNK, lipozom, lipopleks ili polipleks i gdje je lipopleks poželjno formiran od kationskih lipozoma i izborno sadrži neutralni pomoćni lipid.
14. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1 do 13 za uporabu u terapiji, pri čemu terapija obuhvaća primjenu farmaceutske kompozicije kod subjekta.
15. Farmaceutska kompozicija za uporabu prema patentnom zahtjevu 14, gdje je primjena intravenska (i.v.), subkutana (s.c.), intradermalna (i.d.), inhalacijska, intranazalna, intraokularna, intraperitonealna, intersticijalna, bukalna, transdermalna, ili sublingvalna primjena.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/056165 WO2017162266A1 (en) | 2016-03-21 | 2016-03-21 | Rna replicon for versatile and efficient gene expression |
| EP20156693.2A EP3701959B1 (en) | 2016-03-21 | 2017-03-13 | Rna replicon for versatile and efficient gene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220044T1 true HRP20220044T1 (hr) | 2022-04-15 |
Family
ID=55587284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220044TT HRP20220044T1 (hr) | 2016-03-21 | 2017-03-13 | Rnk replikon za univerzalnu i efikasnu ekspresiju gena |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11168337B2 (hr) |
| EP (2) | EP3433369B1 (hr) |
| JP (2) | JP7121443B2 (hr) |
| KR (1) | KR102161607B1 (hr) |
| CN (2) | CN115927467A (hr) |
| AU (1) | AU2017236239B2 (hr) |
| BR (1) | BR112018068381A2 (hr) |
| CA (1) | CA3017272A1 (hr) |
| CY (1) | CY1125086T1 (hr) |
| DK (2) | DK3433369T3 (hr) |
| ES (2) | ES2784711T3 (hr) |
| HK (1) | HK1259449A1 (hr) |
| HR (1) | HRP20220044T1 (hr) |
| HU (2) | HUE059139T2 (hr) |
| IL (2) | IL261379B (hr) |
| LT (1) | LT3701959T (hr) |
| MX (1) | MX2018011383A (hr) |
| PL (2) | PL3433369T3 (hr) |
| PT (2) | PT3433369T (hr) |
| RS (1) | RS62864B1 (hr) |
| RU (1) | RU2748892C2 (hr) |
| SG (1) | SG11201807374WA (hr) |
| SI (2) | SI3701959T1 (hr) |
| WO (2) | WO2017162266A1 (hr) |
| ZA (1) | ZA201805519B (hr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| JP7389741B2 (ja) * | 2017-09-13 | 2023-11-30 | バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー | Ｔ細胞受容体または人工ｔ細胞受容体を発現するためのｒｎａレプリコン |
| CN111094549B (zh) * | 2017-09-13 | 2024-11-01 | 生物技术公司 | 用于将体细胞重编程的rna复制子 |
| AU2020207641A1 (en) | 2019-01-10 | 2021-07-22 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN114341361A (zh) * | 2019-06-10 | 2022-04-12 | 传染病研究所 | 星状病毒复制子的方法和组合物 |
| TW202128775A (zh) | 2019-10-16 | 2021-08-01 | 英商阿法克塔生命科學有限公司 | PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分 |
| PE20221182A1 (es) | 2019-11-18 | 2022-08-05 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| CN110890127B (zh) * | 2019-11-27 | 2024-02-23 | 山东大学 | 酿酒酵母dna复制起始区域识别方法 |
| CN116196405A (zh) | 2019-12-31 | 2023-06-02 | 伊利克斯根治疗公司 | 核酸和蛋白质向细胞和组织的基于温度的瞬时递送 |
| EP4103228A1 (en) | 2020-02-13 | 2022-12-21 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| EP4117720A4 (en) | 2020-03-09 | 2024-04-24 | Arcturus Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES |
| GB2594364A (en) * | 2020-04-22 | 2021-10-27 | Biontech Rna Pharmaceuticals Gmbh | Coronavirus vaccine |
| CN116096409A (zh) * | 2020-05-11 | 2023-05-09 | 杨森制药公司 | 编码稳定化的冠状病毒刺突蛋白的rna复制子 |
| JP2023527910A (ja) * | 2020-06-04 | 2023-06-30 | バイオエヌテック エスエー | 多用途かつ効率的な遺伝子発現のためのｒｎａレプリコン |
| GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
| EP4308136A1 (en) | 2021-03-19 | 2024-01-24 | Tiba Biotech LLC | Artificial alphavirus-derived rna replicon expression systems |
| KR20240006575A (ko) | 2021-04-26 | 2024-01-15 | 앵스띠뛰 파스퇴르 | SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도 |
| WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
| WO2023057567A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
| TW202332694A (zh) | 2021-10-07 | 2023-08-16 | 英商阿凡克塔生命科學公司 | 血清半衰期延長之ｐｄ－ｌ１結合多肽 |
| JP2024539087A (ja) | 2021-10-18 | 2024-10-28 | バイオエヌテック エスエー | 修飾複製可能ｒｎａおよび関連組成物ならびにそれらの使用 |
| CN118451194A (zh) | 2021-10-18 | 2024-08-06 | 生物技术公司 | 用于确定用于提高经修饰可复制rna功能的突变的方法以及相关组合物及其用途 |
| EP4285932A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4401788A1 (en) | 2021-10-22 | 2024-07-24 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4186528A1 (en) | 2021-11-30 | 2023-05-31 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4169534A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide complexes and uses |
| AU2022369405A1 (en) | 2021-10-22 | 2024-05-09 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4286394A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4169578A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4286003A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4402149A1 (en) | 2021-10-22 | 2024-07-24 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4169579A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4401789A1 (en) | 2021-10-22 | 2024-07-24 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4402150A1 (en) | 2021-10-22 | 2024-07-24 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4285933A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4286004A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4169580A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| WO2023153876A1 (ko) | 2022-02-10 | 2023-08-17 | 주식회사 아피셀테라퓨틱스 | Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도 |
| CN114639442B (zh) * | 2022-03-30 | 2024-01-30 | 中国农业科学院农业基因组研究所 | 一种基于单核苷酸多态性预测开放阅读框的方法及系统 |
| WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
| WO2023218243A1 (en) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Lag-3/pd-l1 binding fusion proteins |
| WO2023232747A1 (en) | 2022-05-30 | 2023-12-07 | BioNTech SE | Complexes for delivery of nucleic acids |
| WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
| WO2024068674A1 (en) | 2022-09-26 | 2024-04-04 | BioNTech SE | Nucleic acid complexes and uses thereof |
| WO2024084462A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Nucleic acid complexes and uses thereof |
| WO2024176192A1 (en) | 2023-02-24 | 2024-08-29 | BioNTech SE | Immunogenic compositions |
| EP4442276A1 (en) | 2023-04-07 | 2024-10-09 | Institut Pasteur | Combined antibodies against sarbecoviruses and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002537842A (ja) | 1999-03-09 | 2002-11-12 | ラージ スケール バイオロジー コーポレイション | 外来の配列を発現するための多成分ｒｎａベクター系 |
| US7045335B2 (en) * | 2001-09-06 | 2006-05-16 | Alphavax, Inc. | Alphavirus replicon vector systems |
| WO2004085660A2 (en) * | 2003-03-20 | 2004-10-07 | Alphavax, Inc. | Improved alphavirus replicons and helper constructs |
| WO2008119827A1 (en) * | 2007-04-02 | 2008-10-09 | Fit Biotech Oy | Transreplicase constructs |
| EP2167523B1 (en) | 2007-06-19 | 2014-07-23 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
| CA2689588C (en) * | 2007-06-21 | 2016-08-23 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
| CA2695484C (en) | 2007-08-20 | 2018-05-01 | Glaxo Group Limited | Production method of therapeutic proteins based on codon adaptation |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| RU2625546C2 (ru) | 2010-07-06 | 2017-07-14 | Новартис Аг | Катионные эмульсии "масло-в-воде" |
| CN103384515B (zh) | 2010-08-31 | 2017-02-15 | 诺华有限公司 | 适用于脂质体递送编码蛋白质的rna的脂质 |
| CN103179984A (zh) | 2010-08-31 | 2013-06-26 | 诺华有限公司 | 用于递送免疫原编码rna的peg化脂质体 |
| SI2611467T1 (sl) | 2010-08-31 | 2022-10-28 | Glaxosmithkline Biologicals Sa | Majhni liposomi za dostavo RNA, ki kodira imunogen |
| CN103269713B (zh) * | 2010-10-11 | 2016-01-20 | 诺华有限公司 | 抗原递送平台 |
| CN103796639B (zh) | 2011-07-06 | 2017-05-31 | 诺华股份有限公司 | 阳离子水包油乳液 |
| MX350764B (es) | 2011-07-06 | 2017-09-18 | Novartis Ag | Liposomas con relacion nitrogeno:fosfato (n:p) util para el suministro de moleculas de arn. |
| JP6059220B2 (ja) | 2011-07-06 | 2017-01-18 | ノバルティス アーゲー | 核酸を含む水中油型エマルジョン |
| TR201900264T4 (tr) | 2011-08-31 | 2019-02-21 | Glaxosmithkline Biologicals Sa | İmmünojen şifreleyici rna'nın verilmesi için pegile edilmiş lipozomlar. |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2014071963A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
-
2016
- 2016-03-21 WO PCT/EP2016/056165 patent/WO2017162266A1/en active Application Filing
-
2017
- 2017-03-13 EP EP17710528.5A patent/EP3433369B1/en active Active
- 2017-03-13 EP EP20156693.2A patent/EP3701959B1/en active Active
- 2017-03-13 MX MX2018011383A patent/MX2018011383A/es unknown
- 2017-03-13 US US16/086,157 patent/US11168337B2/en active Active
- 2017-03-13 SI SI201731043T patent/SI3701959T1/sl unknown
- 2017-03-13 KR KR1020187027294A patent/KR102161607B1/ko active IP Right Grant
- 2017-03-13 HU HUE20156693A patent/HUE059139T2/hu unknown
- 2017-03-13 AU AU2017236239A patent/AU2017236239B2/en active Active
- 2017-03-13 WO PCT/EP2017/055808 patent/WO2017162460A1/en active Application Filing
- 2017-03-13 CN CN202210935299.4A patent/CN115927467A/zh active Pending
- 2017-03-13 PL PL17710528T patent/PL3433369T3/pl unknown
- 2017-03-13 DK DK17710528.5T patent/DK3433369T3/da active
- 2017-03-13 LT LTEP20156693.2T patent/LT3701959T/lt unknown
- 2017-03-13 PT PT177105285T patent/PT3433369T/pt unknown
- 2017-03-13 PT PT201566932T patent/PT3701959T/pt unknown
- 2017-03-13 RU RU2018131966A patent/RU2748892C2/ru active
- 2017-03-13 JP JP2018549313A patent/JP7121443B2/ja active Active
- 2017-03-13 CA CA3017272A patent/CA3017272A1/en active Pending
- 2017-03-13 HU HUE17710528A patent/HUE050350T2/hu unknown
- 2017-03-13 SG SG11201807374WA patent/SG11201807374WA/en unknown
- 2017-03-13 BR BR112018068381A patent/BR112018068381A2/pt active Search and Examination
- 2017-03-13 PL PL20156693T patent/PL3701959T3/pl unknown
- 2017-03-13 CN CN201780019155.1A patent/CN108884473B/zh active Active
- 2017-03-13 ES ES17710528T patent/ES2784711T3/es active Active
- 2017-03-13 DK DK20156693.2T patent/DK3701959T3/da active
- 2017-03-13 HR HRP20220044TT patent/HRP20220044T1/hr unknown
- 2017-03-13 RS RS20220067A patent/RS62864B1/sr unknown
- 2017-03-13 SI SI201730212T patent/SI3433369T1/sl unknown
- 2017-03-13 ES ES20156693T patent/ES2906807T3/es active Active
-
2018
- 2018-08-17 ZA ZA201805519A patent/ZA201805519B/en unknown
- 2018-08-26 IL IL261379A patent/IL261379B/en unknown
-
2019
- 2019-02-01 HK HK19101854.2A patent/HK1259449A1/zh unknown
-
2021
- 2021-10-05 US US17/494,601 patent/US20220033852A1/en active Pending
-
2022
- 2022-01-26 CY CY20221100063T patent/CY1125086T1/el unknown
- 2022-03-03 IL IL291100A patent/IL291100B2/en unknown
- 2022-08-02 JP JP2022123058A patent/JP7465310B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220044T1 (hr) | Rnk replikon za univerzalnu i efikasnu ekspresiju gena | |
| US12097253B2 (en) | RSV RNA molecules and compositions for vaccination | |
| US11759515B2 (en) | Compositions and methods for inducing immune responses | |
| Chaudhary et al. | mRNA vaccines for infectious diseases: principles, delivery and clinical translation | |
| US20220211838A1 (en) | Nucleic acid based combination vaccines | |
| ES2890023T3 (es) | Partículas alfavíricas y métodos de preparación | |
| KR102511554B1 (ko) | 핵산의 전달용 입체화학적으로 풍부한 조성물 | |
| US20230270841A1 (en) | Coronavirus vaccine | |
| EP3893927A1 (en) | Heterologous prime boost vaccine compositions and methods | |
| JP2016516415A5 (hr) | ||
| RU2015103891A (ru) | Комплексы белков цитомегаловируса | |
| US20240024455A1 (en) | Multicistronic rna vaccines and uses thereof | |
| US11685906B2 (en) | Compositions and methods for treating ornithine transcarbamylase deficiency | |
| CA3143632A1 (en) | Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof | |
| NZ596823A (en) | Swine influenza hemagglutinin variants | |
| CA2859920C (en) | Variants of yeast ndi1 gene, and uses thereof in the treatment of disease associated with mitochondrial dysfunction | |
| EP4114470A1 (en) | Compositions and methods for the treatment of ornithine transcarbamylase deficiency | |
| AU2022336209A1 (en) | Novel lipid nanoparticles for delivery of nucleic acids | |
| CA3230056A1 (en) | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine | |
| US20200109375A1 (en) | Therapeutics for phenylketonuria | |
| ES2585735T3 (es) | Nuevas proteínas de fusión y su aplicación para la preparación de vacunas contra la hepatitis C | |
| WO2022204549A1 (en) | Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof | |
| US20240301007A1 (en) | Methods and compositions for quadrivalent influenza vaccine | |
| WO1999057284A2 (en) | Attenuated influenza viruses | |
| US20230330218A1 (en) | Hepatitis c virus modified e2 glycoprotein and uses thereof as vaccines |